Intravenous Iron Drugs Market Size, Share & Forecast Analysis to 2030

The global intravenous iron drugs market size was valued at around USD 3.5 billion in 2025 and expected to grow at a significant CAGR of over 9% during the forecast period from 2026 to 2030. The market is witnessing steady growth due to the rising prevalence of iron deficiency anemia, chronic kidney disease, and other conditions requiring rapid iron replenishment. Increasing preference for intravenous therapies over oral iron supplements, owing to faster efficacy and better absorption, is driving market expansion. The North America holds a significant market share due to advanced healthcare infrastructure and high treatment demand.

Market Snapshot:

Key Insights:

• The global intravenous iron drugs market is expected to witness steady growth, driven by the increasing prevalence of iron deficiency anemia and chronic diseases.
• Ferric Carboxymaltose dominates the drug type segment due to its high-dose administration capability, fewer infusion sessions, and favorable safety profile.
• Chronic Kidney Disease (CKD) represents the leading application segment, supported by the widespread use of intravenous iron therapy in anemia management.
• North America holds the largest market share, benefiting from advanced healthcare infrastructure, strong clinical adoption, and favorable reimbursement policies.

Key Factors Driving the Intravenous Iron Drugs Market Growth

The increasing prevalence of iron deficiency anemia and chronic disease-associated anemia is a major factor driving the growth of the intravenous iron drugs market. IV iron therapies are gaining preference among healthcare providers due to their ability to deliver rapid iron replenishment, improve hemoglobin levels, and provide effective treatment for patients who do not respond well to oral iron supplements. The rising burden of anemia, growing geriatric population, increasing prevalence of chronic kidney disease, and expanding use of hospital-based anemia management therapies are further supporting market growth.

According to the World Health Organization (WHO), anemia remains a major global public health concern, affecting approximately 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49 years worldwide. WHO also identifies dietary iron deficiency as one of the largest contributors to anemia globally. This significant disease burden is increasing the demand for effective iron replacement therapies, including intravenous iron drugs, particularly among high-risk patient groups requiring faster correction of iron deficiency.

Key Growth Drivers:

• Rising anemia prevalence globally is increasing demand for intravenous iron therapies among patients requiring rapid iron replenishment and improved outcomes.
• Growing cases of chronic kidney disease, cancer-related anemia, and inflammatory disorders are driving adoption of effective IV iron treatments.
• Advancements in high-dose iron formulations are improving safety, reducing infusion frequency, and enhancing patient convenience across healthcare settings.

Intravenous Iron Drugs Market Restraining Factors

The high cost associated with intravenous iron therapies compared with oral iron supplements is a key factor limiting market growth, particularly in cost-sensitive healthcare systems. Additionally, the requirement for clinical supervision, infusion facilities, and trained healthcare professionals increases treatment expenses and may restrict adoption in low- and middle-income regions. Limited healthcare infrastructure and reimbursement challenges in some countries further impact accessibility to advanced IV iron treatments.

Concerns related to potential adverse reactions, including hypersensitivity responses, infusion-related complications, and the need for patient monitoring during administration, may also hinder market expansion. Furthermore, the availability of alternative oral iron therapies and improvements in oral formulations continue to provide competition, especially among patients with mild to moderate iron deficiency anemia.

Growth Opportunities in the Global Intravenous Iron Drugs Market

The expanding healthcare infrastructure in emerging economies and increasing focus on anemia management are creating significant growth opportunities for intravenous iron drug manufacturers. Rising adoption of outpatient infusion services, improved access to specialty care, and increasing diagnosis of iron deficiency disorders are encouraging broader use of IV iron therapies across hospitals and clinics. The growing application of intravenous iron in chronic kidney disease, heart failure, and inflammatory conditions is also expected to support market expansion.

The development of advanced iron formulations with improved safety profiles, higher dosing capacity, and reduced administration time is creating new opportunities for market players. According to the National Kidney Foundation (NKF), more than 9 out of 10 people with stage 5 chronic kidney disease (kidney failure) have anemia, while nearly half of people with stage 3a CKD in the United States also experience anemia. This high prevalence of CKD-associated anemia highlights the growing need for effective iron replacement therapies, including intravenous iron drugs, among patients with declining kidney function.

Key Growth Opportunities:

• Expanding healthcare infrastructure and improving access to specialty care in emerging economies are creating new opportunities for intravenous iron drug adoption.
• Growing demand for anemia management in chronic kidney disease, heart failure, and inflammatory disorders is increasing the application scope of IV iron therapies.
• Development of advanced iron formulations with improved safety, higher dosing efficiency, and shorter infusion times is supporting future market growth opportunities.

Industry Trends Shaping the Global Intravenous Iron Drugs Market

The increasing adoption of high-dose intravenous iron formulations is a key trend shaping the market, as healthcare providers seek faster and more efficient iron replenishment therapies. Formulations such as ferric carboxymaltose and ferric derisomaltose are gaining wider acceptance because they enable administration of larger iron doses in fewer infusion sessions, improving patient convenience and reducing hospital visits. The expansion of outpatient infusion centers and personalized anemia management is further supporting market growth.

Another notable trend is the growing use of evidence-based treatment protocols for anemia associated with chronic kidney disease. According to the KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease, the updated guideline provides evidence-based recommendations for the diagnosis, evaluation, and management of anemia in adults and children with CKD, including patients undergoing dialysis and kidney transplantation, reflecting the increasing standardization of intravenous iron therapy in clinical practice.

Market Segments Insights:

By Drug Type, the Ferric Carboxymaltose Segment Dominated the Global Intravenous Iron Drugs Market

On the basis of drug type, the ferric carboxymaltose is expected to be the dominant segment in the intravenous iron drugs market due to its ability to deliver high doses of iron in fewer infusion sessions, enabling faster correction of iron deficiency compared with traditional formulations. Its favorable pharmacokinetic profile, improved patient convenience, and reduced treatment frequency have increased adoption among healthcare providers for managing iron deficiency anemia associated with chronic diseases such as chronic kidney disease, heart failure, and inflammatory disorders.

The growing clinical acceptance of ferric carboxymaltose is also supported by regulatory approvals and expanding treatment applications. According to the U.S. Food and Drug Administration (FDA), ferric carboxymaltose injection (Injectafer) is approved for the treatment of iron deficiency anemia in adult patients who have intolerance or an unsatisfactory response to oral iron and for adult patients with non-dialysis-dependent chronic kidney disease. This broad clinical application supports the increasing adoption of ferric carboxymaltose as a leading intravenous iron therapy.

By Application, the Chronic Kidney Disease Sub-category Holds the Largest Share of Global Intravenous Iron Drugs Market

On the basis of application, the chronic kidney disease (CKD) is expected to be the dominant application segment in the intravenous iron drugs market due to the high prevalence of anemia among CKD patients and the extensive use of IV iron therapies in renal care. CKD affects the body’s ability to maintain healthy red blood cell production and iron balance, increasing the need for iron replacement treatments, particularly among patients undergoing dialysis. Intravenous iron is widely preferred in CKD management because it enables faster replenishment of iron stores and supports improved anemia control compared with oral iron therapies.

The rising prevalence of kidney disease and increasing focus on effective anemia management strategies are further strengthening demand for intravenous iron drugs in the CKD segment. According to the Centers for Disease Control and Prevention (CDC), about 1 in 7 adults in the United States are estimated to have chronic kidney disease, highlighting the significant patient population requiring supportive treatments such as anemia management therapies. This growing CKD burden is expected to support continued adoption of intravenous iron drugs in hospitals and dialysis centers.

Global Intravenous Iron Drugs Market Segmentation:

By Drug Type:

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Others

By Application:

• Chronic Kidney Disease (CKD)
• Iron Deficiency Anemia
• Cancer-Associated Anemia
• Inflammatory Bowel Disease (IBD)
• Others

By End-User:

• Hospitals
• Dialysis Centers
• Specialty Clinics
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: The North America Leading the Global Intravenous Iron Drugs Market

Geographically, the North America is expected to dominate the intravenous iron drugs market due to its well-established healthcare infrastructure, high awareness of anemia management, and increasing prevalence of chronic diseases such as chronic kidney disease, heart failure, and cancer. The region has a strong network of hospitals, dialysis centers, and specialty clinics that routinely administer intravenous iron therapies, supported by favorable reimbursement systems and the availability of advanced treatment options.

The region’s leadership is further reinforced by continuous clinical research and evidence-based treatment practices. According to the National Institutes of Health (NIH), iron deficiency is the most common nutritional deficiency worldwide and is a major contributor to anemia, while patients with chronic diseases frequently require intravenous iron therapy when oral iron is ineffective or poorly tolerated. This growing clinical emphasis on effective iron replacement therapies continues to support the widespread adoption of intravenous iron drugs across North America.

Competitive Analysis:

The intravenous iron drugs market is moderately consolidated, with leading companies competing through product innovation, regulatory approvals, clinical research, and geographic expansion. Key market participants include CSL Vifor, Daiichi Sankyo Company, Limited, Pharmacosmos A/S, American Regent, Inc., and Covis Pharma. These companies are focusing on expanding their intravenous iron portfolios, strengthening global distribution networks, and improving treatment outcomes through advanced iron formulations with enhanced safety and dosing efficiency.

Competition is further driven by increasing demand for intravenous iron therapies in the treatment of chronic kidney disease, iron deficiency anemia, heart failure, and other chronic conditions. Market players are investing in research and development, strategic partnerships, and label expansions to strengthen their market presence and meet the growing need for rapid and effective iron replacement therapies. Continuous innovation and regulatory compliance are expected to remain key factors influencing competitive positioning during the forecast period.

Key Companies:

• CSL Vifor
• Daiichi Sankyo Company, Limited
• Pharmacosmos A/S
• American Regent, Inc.
• Covis Pharma
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited
• Abbott Laboratories
• Shield Therapeutics plc
• Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Global Intravenous Iron Drugs Market Outlook

• Rising prevalence of iron deficiency anemia and chronic kidney disease is expected to sustain long-term demand for intravenous iron therapies.
• Increasing adoption of high-dose, rapid-infusion iron formulations will improve treatment efficiency and enhance patient convenience across healthcare settings.
• Expanding healthcare infrastructure and improving access to specialty care in emerging economies will create new growth opportunities for market participants.
• Ongoing clinical research and regulatory approvals are expected to broaden the use of intravenous iron drugs in additional therapeutic applications.
• Strategic investments in product innovation, manufacturing capacity, and global distribution networks will intensify competition and support continued market expansion.

Frequently Asked Questions About the Intravenous Iron Drugs Market